Dmitrij Hrisodorov

Dmitrij Hristodorov is General Partner at Forbion and core member of the investment team working on new investments across funds and therapeutic areas.

 

Before joining Forbion, he held roles in R&D Ophthalmology and Business Development at Bayer Pharma. His current portfolio covers various stages, treatment modalities and disease areas. To date, he serves as a board member for Oxular, ARMGO Pharma, Complement Therapeutics, Seamless Therapeutics, AAVantgarde Bio, Kynexis, and Rampart Bio. He previously served as a board observer of VectorY Therapeutics, and as a board observer and R&D committee member of Gyroscope Therapeutics that was acquired for up to $1.5Bn by Novartis in December 2021. In 2013 he received his PhD degree summa cum laude from the University of Aachen (RWTH) for the work he performed at Fraunhofer Institute in immunology.